Investor updates & Ad hoc announcements Keyword Search Clear 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 29 December 2014 Invitation to Roche's Full Year Results 2014 more Published on: 19 December 2014 Roche provides update on gantenerumab development programme more Published on: 19 December 2014 Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer more Published on: 12 December 2014 Changes in Roche Board of Directors and enlarged Corporate Executive Committee more Published on: 9 December 2014 Roche presents data for hemophilia A therapy ACE910 more Published on: 8 December 2014 Roche launches next-generation viral load testing assays for new molecular diagnostic platforms in markets accepting the CE mark more Published on: 5 December 2014 Roche to present clinical data from six different medicines at ASH more Published on: 2 December 2014 Roche acquires Ariosa Diagnostics and enters the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets more Published on: 17 November 2014 FDA approves Roche’s Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer more Published on: 13 November 2014 Roche Receives FDA Clearance for Strep A Test on cobas Liat System more Published on: 6 November 2014 Reminder: Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting more Published on: 5 November 2014 Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China more Published on: 29 October 2014 Reminder: Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting more Published on: 24 October 2014 CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis (IPF), strengthening mortality benefit and reinforcing safety profile more Published on: 22 October 2014 Roche invests for the future in its Basel site more Published on: 16 October 2014 Roche delivers solid sales growth for the first nine months of 2014 more Published on: 16 October 2014 FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States more Published on: 9 October 2014 Reminder: Invitation to Roche's Third Quarter Sales 2014 Conference Call more Published on: 9 October 2014 Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting more Published on: 8 October 2014 FDA grants Priority Review for Lucentis in diabetic retinopathy more Published on: 29 September 2014 Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab) more Published on: 29 September 2014 Roche presents encouraging update on metastatic bladder cancer data for anti-PDL1 medicine (MPDL3280A) more Published on: 29 September 2014 Roche’s investigational combination of cobimetinib plus Zelboraf® (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone more Published on: 29 September 2014 Roche purchases shares in tender offer for InterMune, Inc. more Published on: 28 September 2014 Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy more Published on: 26 September 2014 Roche launches Global Access Program for HIV viral load testing more Published on: 25 September 2014 Roche's Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies more Published on: 22 September 2014 Reminder: Invitation to Roche's investor science conference call from ESMO 2014 more Published on: 17 September 2014 Roche to present latest oncology advances during ESMO 2014 Congress more Published on: 16 September 2014 Invitation to Roche's Third Quarter Sales 2014 Conference Call more Published on: 15 September 2014 Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA) more Published on: 11 September 2014 Roche again ranked most sustainable healthcare company in the Dow Jones Sustainability Indices more Published on: 8 September 2014 Roche's RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA) more Published on: 5 September 2014 Launch of the Anti-Cancer Agent / ALK Inhibitor “Alecensa” in Japan more Published on: 4 September 2014 Roche announces change in Board of Directors more Published on: 2 September 2014 Roche launches new fully automated molecular diagnostic systems offering the fastest time to results with the highest testing capacity more Published on: 29 August 2014 Roche commences tender offer for InterMune, Inc. for US$74.00 per share in cash more Published on: 26 August 2014 Invitation to Roche's investor science conference call from ESMO 2014 more Published on: 25 August 2014 Reminder: Invitation to Roche investor conference call on the acquisition of InterMune more Published on: 24 August 2014 Roche and InterMune reach definitive merger agreement more Published on: 15 August 2014 FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer more Published on: 6 August 2014 EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer more Published on: 29 July 2014 Roche's Gazyvaro approved in Europe for patients with the most common type of leukemia more Published on: 28 July 2014 Roche's RoACTEMRA receives CHMP positive opinion in Europe for use in patients with early rheumatoid arthritis (RA) not previously treated with methotrexate (MTX) more Published on: 24 July 2014 Roche with good half year performance more Published on: 22 July 2014 Reminder: Roche Analyst Event on Diagnostics Division at AACC 2014 Tuesday, 29 July 2014 more Published on: 22 July 2014 FDA grants Roche's Avastin Priority Review for recurrent platinum-resistant ovarian cancer more Published on: 17 July 2014 Reminder: Invitation to Roche's Half Year Results 2014 more Published on: 16 July 2014 Roche announces phase II clinical results of crenezumab in Alzheimer’s disease more Published on: 15 July 2014 FDA grants Roche's Avastin Priority Review for certain types of cervical cancer more Published on: 14 July 2014 Roche's investigational medicine cobimetinib, used in combination with Zelboraf (vemurafenib), helped people with advanced melanoma live significantly longer without their disease worsening more Published on: 4 July 2014 Japan becomes first country to approve Roche's alectinib for people with a specific form of advanced lung cancer more Published on: 2 July 2014 Roche Analyst Event on Diagnostics Division at AACC 2014 Tuesday, 29 July 2014 more Published on: 2 July 2014 Roche announces definitive agreement to acquire Seragon Pharmaceuticals more Published on: 30 June 2014 Roche launches fully automated urine testing analyzer for enhanced result reliability and staff safety more Published on: 27 June 2014 CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer more Published on: 26 June 2014 Invitation to Roche's Half Year Results 2014 more Published on: 16 June 2014 Roche Children's Walk 2014: Roche employees participate in sponsored walk to support vulnerable children in Malawi and around the world more Published on: 4 June 2014 Save the date: Swiss Sustainability Leaders - 2nd Annual Meeting SRI Conference 2014 more Published on: 2 June 2014 The combination of Roche's Avastin and Tarceva helped people with a specific form of lung cancer live longer without their disease worsening more Published on: 2 June 2014 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2014 more Published on: 2 June 2014 Roche acquires Genia Technologies to strengthen next generation sequencing pipeline more Published on: 1 June 2014 Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis (PVNS) more Published on: 31 May 2014 Roche presents encouraging new data in common blood cancers for its investigational BCL-2 inhibitor GDC-0199/ABT-199 and polatuzumab vedotin, an anti-CD79b antibody drug conjugate more Published on: 31 May 2014 Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study more Published on: 23 May 2014 CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia more Published on: 23 May 2014 Reminder: Invitation to Roche Analyst Event at ASCO 2014 more Published on: 14 May 2014 Roche to present new data on 27 different medicines at ASCO more Published on: 7 May 2014 Roche presents final Phase 1b data on its investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma at EADO 2014 more Published on: 30 April 2014 Invitation to Roche Analyst Event at ASCO 2014 more Published on: 28 April 2014 Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis more Published on: 25 April 2014 FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer more Published on: 17 April 2014 Launch of the Anti-Cancer Agent “Kadcyla®” in Japan more Published on: 15 April 2014 Roche with good start in 2014 more Published on: 8 April 2014 Reminder: Invitation to Roche's First Quarter Sales 2014 Conference Call more Published on: 7 April 2014 Roche acquires IQuum to strengthen offerings in molecular diagnostics more Published on: 28 March 2014 Save the date: Roche Analyst Event at ASCO 2014 more Published on: 28 March 2014 Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma more Published on: 24 March 2014 FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives more Published on: 18 March 2014 Invitation to Roche's First Quarter Sales 2014 Conference Call more Published on: 13 March 2014 FDA Advisory committee unanimously recommends Roche's HPV Test as primary screening tool for detection of women at high risk for cervical cancer more Published on: 7 March 2014 New Roche test helps specialists to identify syphilis in routine samples and donated blood more Published on: 5 March 2014 Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma more Published on: 4 March 2014 Roche Annual General Meeting 2014 more Published on: 3 March 2014 Roche provides update on phase III study of onartuzumab in people with specific type of lung cancer more Published on: 26 February 2014 Reminder: Upcoming changes to the Roche ADR (RHHBY) more Published on: 10 February 2014 Upcoming changes to the Roche ADR (RHHBY) more Published on: 30 January 2014 Roche delivers strong 2013 results more Published on: 24 January 2014 CHMP recommends EU approval of a new formulation of Roche’s MabThera for patients with non-Hodgkin lymphoma more Published on: 21 January 2014 Reminder: Invitation to Roche's Full Year Results for 2013 more Published on: 21 January 2014 Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia more
Published on: 19 December 2014 Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer more
Published on: 12 December 2014 Changes in Roche Board of Directors and enlarged Corporate Executive Committee more
Published on: 8 December 2014 Roche launches next-generation viral load testing assays for new molecular diagnostic platforms in markets accepting the CE mark more
Published on: 5 December 2014 Roche to present clinical data from six different medicines at ASH more
Published on: 2 December 2014 Roche acquires Ariosa Diagnostics and enters the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets more
Published on: 17 November 2014 FDA approves Roche’s Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer more
Published on: 13 November 2014 Roche Receives FDA Clearance for Strep A Test on cobas Liat System more
Published on: 6 November 2014 Reminder: Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting more
Published on: 5 November 2014 Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China more
Published on: 29 October 2014 Reminder: Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting more
Published on: 24 October 2014 CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis (IPF), strengthening mortality benefit and reinforcing safety profile more
Published on: 16 October 2014 Roche delivers solid sales growth for the first nine months of 2014 more
Published on: 16 October 2014 FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States more
Published on: 9 October 2014 Reminder: Invitation to Roche's Third Quarter Sales 2014 Conference Call more
Published on: 9 October 2014 Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting more
Published on: 29 September 2014 Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab) more
Published on: 29 September 2014 Roche presents encouraging update on metastatic bladder cancer data for anti-PDL1 medicine (MPDL3280A) more
Published on: 29 September 2014 Roche’s investigational combination of cobimetinib plus Zelboraf® (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone more
Published on: 28 September 2014 Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy more
Published on: 25 September 2014 Roche's Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies more
Published on: 22 September 2014 Reminder: Invitation to Roche's investor science conference call from ESMO 2014 more
Published on: 17 September 2014 Roche to present latest oncology advances during ESMO 2014 Congress more
Published on: 15 September 2014 Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA) more
Published on: 11 September 2014 Roche again ranked most sustainable healthcare company in the Dow Jones Sustainability Indices more
Published on: 8 September 2014 Roche's RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA) more
Published on: 5 September 2014 Launch of the Anti-Cancer Agent / ALK Inhibitor “Alecensa” in Japan more
Published on: 2 September 2014 Roche launches new fully automated molecular diagnostic systems offering the fastest time to results with the highest testing capacity more
Published on: 29 August 2014 Roche commences tender offer for InterMune, Inc. for US$74.00 per share in cash more
Published on: 26 August 2014 Invitation to Roche's investor science conference call from ESMO 2014 more
Published on: 25 August 2014 Reminder: Invitation to Roche investor conference call on the acquisition of InterMune more
Published on: 15 August 2014 FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer more
Published on: 6 August 2014 EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer more
Published on: 29 July 2014 Roche's Gazyvaro approved in Europe for patients with the most common type of leukemia more
Published on: 28 July 2014 Roche's RoACTEMRA receives CHMP positive opinion in Europe for use in patients with early rheumatoid arthritis (RA) not previously treated with methotrexate (MTX) more
Published on: 22 July 2014 Reminder: Roche Analyst Event on Diagnostics Division at AACC 2014 Tuesday, 29 July 2014 more
Published on: 22 July 2014 FDA grants Roche's Avastin Priority Review for recurrent platinum-resistant ovarian cancer more
Published on: 16 July 2014 Roche announces phase II clinical results of crenezumab in Alzheimer’s disease more
Published on: 15 July 2014 FDA grants Roche's Avastin Priority Review for certain types of cervical cancer more
Published on: 14 July 2014 Roche's investigational medicine cobimetinib, used in combination with Zelboraf (vemurafenib), helped people with advanced melanoma live significantly longer without their disease worsening more
Published on: 4 July 2014 Japan becomes first country to approve Roche's alectinib for people with a specific form of advanced lung cancer more
Published on: 2 July 2014 Roche Analyst Event on Diagnostics Division at AACC 2014 Tuesday, 29 July 2014 more
Published on: 2 July 2014 Roche announces definitive agreement to acquire Seragon Pharmaceuticals more
Published on: 30 June 2014 Roche launches fully automated urine testing analyzer for enhanced result reliability and staff safety more
Published on: 27 June 2014 CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer more
Published on: 16 June 2014 Roche Children's Walk 2014: Roche employees participate in sponsored walk to support vulnerable children in Malawi and around the world more
Published on: 4 June 2014 Save the date: Swiss Sustainability Leaders - 2nd Annual Meeting SRI Conference 2014 more
Published on: 2 June 2014 The combination of Roche's Avastin and Tarceva helped people with a specific form of lung cancer live longer without their disease worsening more
Published on: 2 June 2014 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2014 more
Published on: 2 June 2014 Roche acquires Genia Technologies to strengthen next generation sequencing pipeline more
Published on: 1 June 2014 Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis (PVNS) more
Published on: 31 May 2014 Roche presents encouraging new data in common blood cancers for its investigational BCL-2 inhibitor GDC-0199/ABT-199 and polatuzumab vedotin, an anti-CD79b antibody drug conjugate more
Published on: 31 May 2014 Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study more
Published on: 23 May 2014 CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia more
Published on: 7 May 2014 Roche presents final Phase 1b data on its investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma at EADO 2014 more
Published on: 28 April 2014 Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis more
Published on: 25 April 2014 FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer more
Published on: 8 April 2014 Reminder: Invitation to Roche's First Quarter Sales 2014 Conference Call more
Published on: 7 April 2014 Roche acquires IQuum to strengthen offerings in molecular diagnostics more
Published on: 28 March 2014 Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma more
Published on: 24 March 2014 FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives more
Published on: 13 March 2014 FDA Advisory committee unanimously recommends Roche's HPV Test as primary screening tool for detection of women at high risk for cervical cancer more
Published on: 7 March 2014 New Roche test helps specialists to identify syphilis in routine samples and donated blood more
Published on: 5 March 2014 Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma more
Published on: 3 March 2014 Roche provides update on phase III study of onartuzumab in people with specific type of lung cancer more
Published on: 24 January 2014 CHMP recommends EU approval of a new formulation of Roche’s MabThera for patients with non-Hodgkin lymphoma more
Published on: 21 January 2014 Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia more